LANXESS to showcase Biosecurity Solutions at EuroTier 2022
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The acquisition is for an enterprise value of Rs. 218 crores
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
Government Ayurveda College & Hospital will include an infrastructure for the College and a 100 bedded hospital, hostel block for students and staff quarters.
The company will address the observations within a stipulated timeline working with the regulators
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
Subscribe To Our Newsletter & Stay Updated